Parameters Driving the Selection of Nelfinavir-Resistant Human Immunodeficiency Virus Type 1 Variants
Open Access
- 15 September 2003
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (18), 10172-10175
- https://doi.org/10.1128/jvi.77.18.10172-10175.2003
Abstract
We investigated the parameters driving nelfinavir resistance, along the D30N and L90M evolutionary pathways. The advantage of the D30N mutant was mostly due to its resistance level, while the L90M mutation allowed preservation of infectivity coupled with minimal resistance. Emergence of secondary mutations further increased the selective advantage of viruses harboring D30N.Keywords
This publication has 10 references indexed in Scilit:
- Nelfinavir-Resistant, Amprenavir-Hypersusceptible Strains of Human Immunodeficiency Virus Type 1 Carrying an N88S Mutation in Protease Have Reduced Infectivity, Reduced Replication Capacity, and Reduced Fitness and Process the Gag Polyprotein Precursor AberrantlyJournal of Virology, 2002
- Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2002
- Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of DrugJournal of Virology, 2000
- Antiretroviral Drug Resistance Testing in Adult HIV-1 InfectionJAMA, 2000
- HIV drug resistance and viral fitnessPublished by Elsevier ,2000
- The HIV Type 1 Protease Inhibitor Saquinavir Can Select for Multiple Mutations that Confer Increasing ResistanceAIDS Research and Human Retroviruses, 1999
- Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor NelfinavirAntimicrobial Agents and Chemotherapy, 1998
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors.1995
- Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaquesAIDS, 1995